Ke HW, Zhang WY, Xu KX. Letter to the editor: Aggressive variant prostate cancer: An exemplary case study and comprehensive literature survey. World J Clin Cases 2023; 11(35): 8431-8433 [PMID: 38130605 DOI: 10.12998/wjcc.v11.i35.8431]
Corresponding Author of This Article
Ke-Xin Xu, MD, Full Professor, Surgeon, Department of Urology, Peking University People’s Hospital, Peking University People’s Hospital, No. 11 Xizhimen South Street, Beijing 100044, China. cavinx@yeah.net
Research Domain of This Article
Urology & Nephrology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Dec 16, 2023; 11(35): 8431-8433 Published online Dec 16, 2023. doi: 10.12998/wjcc.v11.i35.8431
Letter to the editor: Aggressive variant prostate cancer: An exemplary case study and comprehensive literature survey
Han-Wei Ke, Wei-Yu Zhang, Ke-Xin Xu
Han-Wei Ke, Wei-Yu Zhang, Ke-Xin Xu, Department of Urology, Peking University People's Hospital, Beijing 100044, China
Co-first authors: Han-Wei Ke and Wei-Yu Zhang.
Author contributions: Xu KX designed research; Ke HW and Zhang WY performed research; Ke HW wrote the letter; Zhang WY revised the letter.
Conflict-of-interest statement: All the authors declare that they have no competing interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ke-Xin Xu, MD, Full Professor, Surgeon, Department of Urology, Peking University People’s Hospital, Peking University People’s Hospital, No. 11 Xizhimen South Street, Beijing 100044, China. cavinx@yeah.net
Received: September 19, 2023 Peer-review started: September 19, 2023 First decision: November 20, 2023 Revised: November 20, 2023 Accepted: December 4, 2023 Article in press: December 4, 2023 Published online: December 16, 2023
Abstract
This article enthusiastically explores the study of highly aggressive variant prostate cancer (AVPC), acknowledging its relatively rare yet highly menacing presence within the realm of prostate cancer. The paper delves into the pathological characteristics of AVPC, diagnostic and therapeutic challenges, and the potential applications of precision medicine and molecular imaging in the future.
Core Tip: Highly aggressive variant prostate cancer presents a formidable challenge in the landscape of prostate malignancies due to its rare but remarkably lethal nature. Understanding its distinctive features and exploring innovative diagnostic and therapeutic approaches, including precision medicine and molecular imaging, are essential for improving patient outcomes and advancing our knowledge in this field.
